AOP Orphan Pharmaceuticals AG (AOP Orphan) announced that based on phase II data it will initiate a phase III trial to support European Marketing Authorization of a novel mono-pegylated Interferon alpha 2b (AOP2014/P1101) for treatment of Polycythemia Vera (PV). Data from 41 PV patients sho ... more
To use all functions of this page, please activate cookies in your browser.
